Checkpoint refractoriness in testicular germ cell tumors: immune-privileged origins, spatial T-cell dysfunction, and histotype-specific evasion programs

Testicular germ cell tumors (TGCTs), especially seminomas, often contain abundant immune infiltrates and express checkpoint-associated molecules. Yet immune checkpoint inhibitors have shown limited activity in unselected cohorts of heavily pretreated germ cell tumors. Immune infiltration alone therefore does not indicate that antitumor immunity can be restored therapeutically. Although TGCTs arise in an immune-privileged organ, the blood-testis barrier cannot account for immune escape at extratesticular metastatic sites. Histotype-specific antigen-presentation differences, tumor-proximal T-cell dysfunction, and regional myeloid or regulatory niches suggest that immune recognition, spatial contact, and effector activity may become uncoupled. We propose a testable model that links checkpoint benefit to retained tumor recognition and reversible local inhibition. Non-canonical checkpoints, including CD24-mediated restriction of macrophage clearance, extend this model as hypotheses requiring TGCT-specific validation. Most available evidence concerns primary orchiectomy tissue rather than post-platinum metastases. Paired longitudinal profiling, component-specific functional experiments, and biomarker-enriched trials should clarify which barriers are therapeutically reversible.